Consensus PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris Other stock markets 03:30:00 06/05/2024 am IST			5-day change	1st Jan Change
2.925 ^EUR	+1.74%		-1.18%	-36.41%

15/04	Phaxiam initiates trial in infective endocarditis	CF
15/04	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

72a196bbfbc0e0cae5f3176270a56a.vRe5u0Sexw9ctDD1Yc1DLg4xxvcVTP7XcKsCZHeAVV4.kCbX8SzqhT4o7kSXGLp7aEYC66d7fciSA_xBCDOxHyb7Yf_dIPC1fBOMUw~0b1f096cf328144b2b2348ac7fe4143b

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.94 EUR

Average target price

6.85 EUR

Spread / Average Target

+132.99%

High Price Target

8 EUR

Spread / Highest target

+172.11%

Low Price Target

5.7 EUR

Spread / Lowest Target

+93.88%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar